Early dexamethasone treatment for septic shock patients: A prospective randomized clinical trial

Sao Paulo Medical Journal

Volumn 125, Issue 4, 2007, Pages 237-241

  Cicarelli, Domingos Dias ^a,b   Vieira, Joaquim Edson ^a   Benseñor, Fábio Ely Martins ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Dexamethasone; Glucocorticoids; Infection; Sepsis; Septic shock

Indexed keywords

DEXAMETHASONE; HYPERTENSIVE FACTOR; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MULTIPLE ORGAN FAILURE; PATIENT MONITORING; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SEPTIC SHOCK; SIDE EFFECT; SUPERINFECTION; TREND STUDY;

EID: 36749079427     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802007000400009     Document Type: Article

References (24)

1. Hotchkiss RS, Kul IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-50.
2. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131-8.
3. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283-6.
4. Briegel J, Forst H, Haller M, et al. Stress of hyrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4)-723-32.
5. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159-65.
6. Carlet J: International Sepsis Forum. Immunoloigcal therapy in sepsis: currently available. Intensive Care Med. 2001;27 (Suppl 1):S93-103.
7. Cicarelli DD, Bensefior FE, Vieira JE. Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J. 2006;124(2):90-5.
8. Schimmer BP, Parker KL. Adrenocurticotropic hormone; adrenocurtical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gihout AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill 1996. p. 1459-85.
9. Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora's Box. Anaeathesia. 2003;58(l):1-3.
10. Cook R, Cook D, Tilley J, Lee K, Marshall J; Canadian Critical Care Trials Group. Multiple organ dysfunction: baseline and serial component scores. Crit Care Med. 2001;29(11):2046-50.
11. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10.
12. Vincent JL, de Mendonça A. Cantraine F, et al. Use of the SOFA score to assess the incidence oforgan dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-relatcd problems"of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
13. Pettilä V, Pettila M, Sarna S, Vourilainen R Takkunen O. Comparison of multiple organ dysfunction scores, in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705-11.
14. Póvoa R Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052-6.
15. Hollenberg SM, Ahrens TS, Annane D. et al. Practice parameters for hemodynamic suppon of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928-48.
16. Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR. Medical epidemiology. 3rd ed. New York McGraw-Hill; 2001.
17. MacLaren R, Jung R. Stress-dose corticosteroids therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140-56.
18. Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668-75.
19. Abraham E, Evans T. Corricosteroids and septic shock. JAMA. 2002;288(7):886-7.
20. Annane D, Sébille V. Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862-71.
21. Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627-30.
22. Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630-3.
23. Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253-7.
24. Martin GS, Bernard GR; International Sepsis Forum. Airway and long in sepsis. Intensive Care Med. 2001;27(Suppl 1):S63-79.